{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06493409",
            "orgStudyIdInfo": {
                "id": "CA127-1072"
            },
            "organization": {
                "fullName": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants",
            "officialTitle": "A Phase I, Two-part, Single-center, Open-label, Drug-drug Interaction Study to Assess the Effect of Voriconazole (Part 1) and Quinidine (Part 2) on the Pharmacokinetics of a Single Dose of Repotrectinib (BMS-986472) in Healthy Participants",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-assess-the-effect-of-voriconazole-and-quinidine-on-the-pharmacokinetics-of-a-single-dose-of-repotrectinib-in-healthy-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": true,
                "nctId": "NCT05926232",
                "statusForNctId": "AVAILABLE"
            },
            "startDateStruct": {
                "date": "2024-08-27",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-25",
            "studyFirstSubmitQcDate": "2024-07-08",
            "studyFirstPostDateStruct": {
                "date": "2024-07-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the effects of coadministration of voriconazole or quinidine on the pharmacokinetics (PK) of repotrectinib in healthy male and female (individual not of childbearing potential \\[INOCBP\\]) participants."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers"
            ],
            "keywords": [
                "drug interaction",
                "healthy",
                "repotrectinib",
                "BMS-986472",
                "pharmacokinetics"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Repotrectinib",
                        "Drug: Voriconazole"
                    ]
                },
                {
                    "label": "Part 2",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Repotrectinib",
                        "Drug: Quinidine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Repotrectinib",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part 1",
                        "Part 2"
                    ],
                    "otherNames": [
                        "BMS-986472"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Voriconazole",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part 1"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Quinidine",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part 2"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum observed plasma concentration (Cmax)",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))",
                    "timeFrame": "Up to Day 23"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants with Adverse Events (AEs)",
                    "timeFrame": "Up to Day 52"
                },
                {
                    "measure": "Number of participants with Severe Adverse Events (SAEs)",
                    "timeFrame": "Up to Day 52"
                },
                {
                    "measure": "Number of participants with physical examination abnormalities",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Number of participants with vital sign abnormalities",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Number of participants with electrocardiogram abnormalities",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Number of participants with clinical safety laboratory test abnormalities",
                    "timeFrame": "Up to Day 22"
                },
                {
                    "measure": "Time of maximum observed plasma concentration (Tmax)",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Apparent terminal phase half-life (T-HALF)",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Apparent total body clearance (CLT/F)",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Apparent volume of distribution of terminal phase (Vz/F)",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Cmax",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Area under the plasma concentration-time curve over one dosing interval (AUC(TAU))",
                    "timeFrame": "Up to Day 23"
                },
                {
                    "measure": "Trough observed plasma concentration (Ctrough)",
                    "timeFrame": "Up to Day 23"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n* Healthy male and female individual(s) not of childbearing potential (INOCBP) participants of any race or ethnicity, as determined by no clinically significant findings in medical history, physical examination, 12-lead ECG, or vital signs as determined by the investigator or designee.\n* Potassium, magnesium, and calcium at or above the lower limit of normal. For other clinical laboratory parameters, no clinically significant findings as determined by the investigator or designee.\n* Must have a body mass index between 18 and 30 kg/m2 (inclusive) and body weight \u2265 50 kg at the time of signing the ICF.\n\nExclusion Criteria\n\n* History of clinically significant acute or chronic medical illness, such as endocrine, gastrointestinal (GI), cardiovascular, peripheral vascular, hematological, hepatic, immunological, renal, respiratory, neoplastic, or genitourinary abnormalities/diseases as determined by the investigator or designee.\n* History of GI disease or surgery that could possibly affect drug absorption, distribution, metabolism, and excretion (ADME) (eg, bariatric procedure, cholecystectomy). Uncomplicated appendectomy and hernia repair are acceptable.\n* Gilbert's syndrome.\n* Other protocol-defined Inclusion/Exclusion criteria apply.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Clinical Trials Contact Center www.BMSClinicalTrials.com",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clinical.Trials@bms.com"
                },
                {
                    "name": "First line of email MUST contain NCT # and Site #.",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Local Institution - 0001",
                    "city": "Daytona Beach",
                    "state": "Florida",
                    "zip": "32117",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site 0001",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.21081,
                        "lon": -81.02283
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "http://www.fda.gov/safety/medwatch"
                },
                {
                    "label": "BMS Clinical Trial Patient Recruiting",
                    "url": "https://www.BMSStudyConnect.com"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.\n\nAdditional information regarding Bristol Myer Squibb's data sharing policy and process can be found at:\n\nhttps://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "CSR"
            ],
            "timeFrame": "See Plan Description",
            "accessCriteria": "See Plan Description",
            "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000065819",
                    "term": "Voriconazole"
                },
                {
                    "id": "D000011802",
                    "term": "Quinidine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000935",
                    "term": "Antifungal Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000058888",
                    "term": "14-alpha Demethylase Inhibitors"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000065692",
                    "term": "Cytochrome P-450 CYP3A Inhibitors"
                },
                {
                    "id": "D000000317",
                    "term": "Adrenergic alpha-Antagonists"
                },
                {
                    "id": "D000018674",
                    "term": "Adrenergic Antagonists"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000000889",
                    "term": "Anti-Arrhythmia Agents"
                },
                {
                    "id": "D000000962",
                    "term": "Antimalarials"
                },
                {
                    "id": "D000000981",
                    "term": "Antiprotozoal Agents"
                },
                {
                    "id": "D000000977",
                    "term": "Antiparasitic Agents"
                },
                {
                    "id": "D000018727",
                    "term": "Muscarinic Antagonists"
                },
                {
                    "id": "D000018680",
                    "term": "Cholinergic Antagonists"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000061567",
                    "term": "Voltage-Gated Sodium Channel Blockers"
                },
                {
                    "id": "D000026941",
                    "term": "Sodium Channel Blockers"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000065690",
                    "term": "Cytochrome P-450 CYP2D6 Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M30607",
                    "name": "Voriconazole",
                    "asFound": "Obstruction",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14652",
                    "name": "Quinidine",
                    "asFound": "Likelihood",
                    "relevance": "HIGH"
                },
                {
                    "id": "M236803",
                    "name": "Quinidine gluconate",
                    "relevance": "LOW"
                },
                {
                    "id": "M6252",
                    "name": "Clotrimazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M11796",
                    "name": "Miconazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M4254",
                    "name": "Antifungal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30564",
                    "name": "Cytochrome P-450 CYP3A Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M3669",
                    "name": "Adrenergic alpha-Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20755",
                    "name": "Adrenergic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4213",
                    "name": "Anti-Arrhythmia Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4280",
                    "name": "Antimalarials",
                    "relevance": "LOW"
                },
                {
                    "id": "M4298",
                    "name": "Antiprotozoal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4294",
                    "name": "Antiparasitic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20801",
                    "name": "Muscarinic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20760",
                    "name": "Cholinergic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M23177",
                    "name": "Sodium Channel Blockers",
                    "relevance": "LOW"
                },
                {
                    "id": "M30025",
                    "name": "Diuretics, Potassium Sparing",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnArAg",
                    "name": "Anti-Arrhythmia Agents"
                },
                {
                    "abbrev": "ChanBlk",
                    "name": "Channel Blockers"
                }
            ]
        }
    },
    "hasResults": false
}